A Phase I Trial of IMA970A Plus Montanide in Combination With Durvalumab (Anti-PD-L1)
Conditions: Hepatocellular Carcinoma Interventions: Biological: Peptide-based hepatocellular carcinoma vaccine IMA970A; Combination Product: Durvalumab; Other: Montanide (Adjuvant) Sponsors: National Cancer Institute, Naples Recruiting
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials
More News: Cancer | Cancer & Oncology | Cancer Vaccines | Carcinoma | Hepatocellular Carcinoma | Liver Cancer | Research | Vaccines